Epigenomics (EPGNY) News Today $2.39 0.00 (0.00%) As of 04/6/2023 Add Compare Share Share Headlines Stock AnalysisBuy This Stock EPGNY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period EQS-News: Epigenomics AG publishes financial results for fiscal year 2023March 14, 2024 | markets.businessinsider.comEQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive BoardJanuary 31, 2024 | markets.businessinsider.comEQS-Adhoc: Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023October 10, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023October 10, 2023 | markets.businessinsider.comCardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in EpigenomicsSeptember 20, 2023 | finance.yahoo.comNew Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General MeetingSeptember 14, 2023 | benzinga.comEQS-News: Epigenomics AG publishes financial results for the first six months 2023August 10, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG Announces Successful Agreement on the Acquisition of Significant AssetsJuly 24, 2023 | markets.businessinsider.comNew Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AGJuly 24, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of Epigenomics AG (ETR:ECX1)July 3, 2023 | finance.yahoo.comEpigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5 MlnJune 12, 2023 | marketwatch.comEpigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak ResignsMay 19, 2023 | uk.news.yahoo.comEQS-News: Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak ResignsMay 19, 2023 | markets.businessinsider.comEpigenomics AG: Chief Executive Officer Greg Hamilton ResignsApril 13, 2023 | uk.finance.yahoo.comEQS-Adhoc: Epigenomics AG: Changes in the ManagementApril 12, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG: Chief Executive Officer Greg Hamilton ResignsApril 12, 2023 | markets.businessinsider.comEpigenomics AG: Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation ActMarch 20, 2023 | uk.finance.yahoo.comSample Preparation in Genomics, Proteomics, and Epigenomics Global Market Report 2023: Increased R&D Spending in Developing Economies Boosts SectorMarch 14, 2023 | benzinga.comEpigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)March 10, 2023 | uk.finance.yahoo.comPersonalized Medicine and Epigenomics Market Capitalizing on Market Growth: Essential Insights from Our Latest Research ReportFebruary 21, 2023 | marketwatch.comEpigenomics AG: Resignation of Supervisory Board Chairman Heino von ProndzynskiJanuary 27, 2023 | uk.finance.yahoo.comEQS-News: Epigenomics AG: Resignation of Supervisory Board Chairman Heino von ProndzynskiJanuary 27, 2023 | markets.businessinsider.comEQS-News: Pareto Securities AS publishes buy recommendation for Epigenomics AG shareDecember 23, 2022 | markets.businessinsider.comEQS-Adhoc: Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022December 21, 2022 | markets.businessinsider.comEQS-Adhoc: Epigenomics Releases Performance Data on Next Generation TestDecember 14, 2022 | markets.businessinsider.comEpigenomics Releases Performance Data on Next Generation TestDecember 14, 2022 | uk.finance.yahoo.comEQS-News: Epigenomics Releases Performance Data on Next Generation TestDecember 14, 2022 | markets.businessinsider.comEQS-News: Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer TestDecember 14, 2022 | markets.businessinsider.comEpigenomics Reports Third Quarter 2022 EarningsNovember 12, 2022 | yahoo.comEQS-Adhoc: Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costsSeptember 19, 2022 | markets.businessinsider.comEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer testSeptember 19, 2022 | uk.finance.yahoo.comEQS-News: Epigenomics Initiates prospective multi-center clinical trial for Next-Generation blood-based colorectal cancer testSeptember 19, 2022 | markets.businessinsider.comDGAP-Adhoc: Epigenomics AG: Capital reduction planned at a ratio of 4 : 1September 9, 2022 | markets.businessinsider.comEpigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktGAugust 15, 2022 | uk.finance.yahoo.comDGAP-News: Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktGAugust 15, 2022 | markets.businessinsider.comDGAP-News: Epigenomics AG Reports Financial Results for the First Six Months of 2022August 10, 2022 | markets.businessinsider.comEpigenomics AG Reports Financial Results for the First Quarter of 2022May 11, 2022 | uk.finance.yahoo.comDGAP-News: Epigenomics AG Reports Financial Results for the First Quarter of 2022May 11, 2022 | markets.businessinsider.comGlobal Personalized Medicine and Epigenomics Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028March 30, 2022 | marketwatch.comDGAP-News: Epigenomics AG Reports Financial Results for Fiscal Year 2021March 24, 2022 | markets.businessinsider.comEPGNY After-Hours QuotesJanuary 14, 2022 | nasdaq.comEPGNY Real-Time QuotesJanuary 6, 2022 | nasdaq.comDGAP-News: Epigenomics AG publishes financial results for the first nine months 2021November 10, 2021 | markets.businessinsider.comEpigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 millionSeptember 13, 2021 | uk.finance.yahoo.comEpigenomics AG: Execution of a Biobank Sale Agreement and Update of GuidanceAugust 17, 2021 | uk.finance.yahoo.com Get Epigenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for EPGNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPGNY Media Mentions By Week EPGNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPGNY News Sentiment▼0.000.71▲Average Medical News Sentiment EPGNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPGNY Articles This Week▼00▲EPGNY Articles Average Week Get the Latest News and Ratings for EPGNY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Epigenomics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BIAFW News IZOZF News MEDD News SBLOF News SKHCF News WUXIF News WUXAY News TGIFF News FFNTF News SXTPW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:EPGNY) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epigenomics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Epigenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPGNY Stock Alerts